Hong Kong-listed biotech firm Innovent Biologics (1801.HK) saw its shares soar 5.17% in intraday trading on Friday, following news that its third-generation EGFR TKI drug Limertinib received approval from China's medical regulator NMPA for treatment of a certain mutation in non-small cell lung cancer.
Limertinib targets the EGFR T790M mutation, which is present in up to 50% of Asian lung cancer patients with locally advanced or metastatic non-small cell lung cancer. This regulatory milestone clears the way for Innovent to market the drug and potentially opens up a significant revenue stream for the biotech firm.
The approval boosts Innovent's oncology drug pipeline and is a major win as it seeks to expand its portfolio of marketed products beyond its existing PD-1 antibody Tyvyt. Investors cheered the development, betting that Limertinib can become a blockbuster therapy given the high prevalence of the targetted mutation in Asian patient populations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.